OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Stock Based Compensation

Last Annual Value

268.30K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

OT

OS Therapies Incorporated Competitors Analysis of Stock Based Compensation

OSTX · NYSE
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
268.30K
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
1.41M
51.1%9.4%N/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
829.10K
5.3%-13.6%-14.5%
5.04M
-26.4%-17.8%N/A
4.74M
-16.6%-16.3%18.2%
5.29M
N/AN/AN/A
6.25M
-8.0%8.8%N/A
2.57M
-17.7%-8.2%N/A
1.22M
36.5%-8.5%N/A
228.00K
-16.2%-50.6%N/A
8897.89B
11606.0%1686.7%285.0%
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42